The Food and Drug Administration on Monday approved AstraZeneca and Sanofi’s shot that protects infants and toddlers against respiratory syncytial virus, which is the leading cause of hospitalization among babies in the U.S.
  • Another Person @lemmy.worldEnglish
    2·
    1 year ago

    It seems this is not a vaccine but instead injectable antibodies. I’d be curious the longevity of such a therapy as well as what the risks are of those antibodies being triggered by a different disease or how it would affect those with an autoimmune disease.

    • Hogger85b@kbin.social
      2·
      1 year ago

      Also what effect does it have on child getting own antibodies to rsv. If you give it to infant are they then able to fight of rsv with their own self made.antibodies at age two or will they need more synthetic ones. At least a vaccine boosts own system